You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ANXA2 Expression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ANXA2 in Extracellular Space in Microenvironment of Periumoral

Recruiting
  • Glioma
  • expression level of ANXA2 protein
  • Beijing, Beijing, China
    Peking University Third Hospital
Jul 7, 2021

ANXA5 M2 Haplotyping in IVF Patients and Embryos

Recruiting
  • Infertility
  • +2 more
  • M2 Test
  • North Brunswick, New Jersey
    Genomic Prediction Clinical Laboratory
Aug 1, 2022

MOLecuLar Signature in Locally Advanced Cervical Cancer Patients

Recruiting
  • Cervical Cancer
  • Tumor tissue
  • Blood sample
  • Rome, Italy
    Policlinico Universitario Agostino Gemelli, IRCCS
Aug 28, 2023

HER2 Expression and Clinical Pathological Characteristics in

Recruiting
  • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
  • Collect HER2 expression in prostate cancer patients
  • Jinan, Shandong, China
    Qilu hospital
Nov 17, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER-2 Expression in Pancreatic Duct Adenocarcinoma

Completed
  • Pancreatic Adenocarcinoma
  • immunohistochemical approach
  • (no location specified)
Sep 20, 2023

Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of

Active, not recruiting
  • Diabetic Nephropathy
  • Grouping based on previous laboratory results, no intervention.
  • Jinan, Shandong, China
    Qianfoshan Hospital
Oct 24, 2023

Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation

Active, not recruiting
  • Diabetic Nephropathy
  • Grouping based on previous laboratory results, no intervention.
  • Jinan, Shandong, China
    Qianfoshan Hospital
Nov 8, 2023

Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)

Not yet recruiting
  • Aortic Valve Stenosis
  • Myocardium biopsy
  • Strasbourg, France
    Hôpitaux Universitaires de Strasbourg
Apr 13, 2023

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Pancreas Cancer Trial (mRNA expression)

Not yet recruiting
  • Pancreas Cancer
  • mRNA expression
  • (no location specified)
Aug 8, 2022

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Lung Cancer Circulating Tumor Cells

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Sample
  • Nice, France
    CHU de Nice
Dec 5, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

Ghrelin and Diastolic Heart Function

Completed
  • Diabetes Mellitus, Type 2
  • +2 more
  • abdominal plastic intervention
  • Naples, Italy
    Celestino Sardu
Aug 4, 2023

Prostate Cancer Trial (Darolutamide Oral Tablet [Nubeqa])

Not yet recruiting
  • Prostate Cancer
  • Darolutamide Oral Tablet [Nubeqa]
  • (no location specified)
Jun 2, 2023

Endometrial Carcinoma Cellular Diagnosis Trial (1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2

Completed
  • Endometrial Carcinoma Cellular Diagnosis
  • 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
  • (no location specified)
Jul 16, 2023